Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Ozempic
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk’s blockbuster drug Ozempic got another star added to its label Thursday, in an encouraging sign for the broadening of the markets for GLP-1 drugs beyond weight-loss and diabetes. Yet, strides by its U.
Ozempic maker Novo Nordisk to boost production through acquisition
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth $11.7 billion.
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision was based on findings of a trial,
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction.
Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update
The decision was based on findings of the FLOW trial, which assessed the risk reduction from Ozempic therapy, a once-weekly subcutaneous semaglutide, in chronic kidney disease-related events. The randomized,
Novo Nordisk says Catalent buyout to close soon
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory conditions to buy the U.
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent
Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
2h
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
1d
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
FiercePharma
2d
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...
9d
Novo Nordisk to cut US list prices of two insulin products by more than 70%
Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...
Business Insider
2d
Novo Nordisk’s Ozempic® Gains EMA Positive Opinion for Kidney Disease Risk Reduction
Pick the best stocks and maximize your portfolio:
Novo
Nordisk
( (NVO)) has provided an update.
Novo
Nordisk
announced that the European Medicines Agency’s Committee for Medicinal Products for ...
1d
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
FierceBiotech
2d
Evotec, Novo Nordisk's drug discovery accelerator debuts first 3 projects, adds 5 partners
LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...
Indiana Daily Student
19h
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ozempic
Catalent
United States
European Medicines Agency
Massachusetts
Feedback